OncoCyte Corp
NASDAQ:OCX

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
NASDAQ:OCX
Watchlist
Price: 2.21 USD 0.91%
Market Cap: 37.2m USD
Have any thoughts about
OncoCyte Corp?
Write Note

Gross Margin
OncoCyte Corp

-16.2%
Current
-47%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-16.2%
=
Gross Profit
-115k
/
Revenue
709k

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
OncoCyte Corp
NASDAQ:OCX
36.9m USD
-16%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
142B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country US
Market Cap 36.9m USD
Gross Margin
-16%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.2B USD
Gross Margin
67%
Country US
Market Cap 142B USD
Gross Margin
60%
Country US
Market Cap 115B USD
Gross Margin
78%
Country US
Market Cap 101.6B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78.5B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

OncoCyte Corp
Glance View

Market Cap
37.2m USD
Industry
Biotechnology

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

OCX Intrinsic Value
2.67 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-16.2%
=
Gross Profit
-115k
/
Revenue
709k
What is the Gross Margin of OncoCyte Corp?

Based on OncoCyte Corp's most recent financial statements, the company has Gross Margin of -16.2%.